BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32705219)

  • 41. Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.
    Ji K; Wang B; Shao YT; Zhang L; Liu YN; Shao C; Li XJ; Li X; Hu JD; Zhao XJ; Xu DQ; Li Y; Cai L
    J Pharmacol Exp Ther; 2011 Jul; 338(1):173-83. PubMed ID: 21444629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of ellagic acid on prostate cancer cell proliferation: a caspase-dependent pathway.
    Malik A; Afaq S; Shahid M; Akhtar K; Assiri A
    Asian Pac J Trop Med; 2011 Jul; 4(7):550-5. PubMed ID: 21803307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. F-box protein FBXO31 modulates apoptosis and epithelial-mesenchymal transition of cervical cancer via inactivation of the PI3K/AKT-mediated MDM2/p53 axis.
    Liu K; Xue B; Bai G; Zhang W
    Life Sci; 2020 Oct; 259():118277. PubMed ID: 32800832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells.
    Gu H; Wang X; Rao S; Wang J; Zhao J; Ren FL; Mu R; Yang Y; Qi Q; Liu W; Lu N; Ling H; You Q; Guo Q
    Mol Cancer Ther; 2008 Oct; 7(10):3298-305. PubMed ID: 18852133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
    Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy.
    Sun SH; Zheng M; Ding K; Wang S; Sun Y
    Cancer Biol Ther; 2008 Jun; 7(6):845-52. PubMed ID: 18340116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
    Xiong J; Li J; Yang Q; Wang J; Su T; Zhou S
    Breast Cancer Res; 2017 Mar; 19(1):27. PubMed ID: 28274247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
    Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
    Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
    Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
    Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line.
    Liu XH; Kirschenbaum A; Yu K; Yao S; Levine AC
    J Biol Chem; 2005 Feb; 280(5):3817-23. PubMed ID: 15550400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
    Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
    Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Counteracting MDM2-induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells.
    Nardinocchi L; Puca R; Givol D; D'Orazi G
    FEBS Lett; 2010 Oct; 584(19):4253-8. PubMed ID: 20849851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
    Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
    Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.
    Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE
    Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2.
    Liu T; Xiong J; Yi S; Zhang H; Zhou S; Gu L; Zhou M
    Oncogene; 2017 Mar; 36(12):1678-1686. PubMed ID: 27617579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.